home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.13 -0.18 (-0.84%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

34 35 Next >

Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

August 15, 2023

Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades.

Via Benzinga

$3M Bet On Tidewater? Check Out These 4 Stocks Insiders Are Buying ↗

August 14, 2023

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

Via Benzinga

Analyst Ratings for Sarepta Therapeutics ↗

August 03, 2023

Via Benzinga

Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript ↗

August 02, 2023

SRPT earnings call for the period ending June 30, 2023.

Via The Motley Fool

Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments

August 02, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Earnings Preview: Sarepta Therapeutics ↗

August 01, 2023

Via Benzinga

2 Biotech Growth Stocks I'd Buy Right Now ↗

July 27, 2023

Both drugmakers seem to have a bright future ahead.

Via The Motley Fool

Where Sarepta Therapeutics Stands With Analysts ↗

July 14, 2023

Via Benzinga

What 25 Analyst Ratings Have To Say About Sarepta Therapeutics ↗

June 23, 2023

Via Benzinga

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results

July 26, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

3 Biotech Stocks to Sell Before They Damage Your Portfolio ↗

July 12, 2023

With the Street generally bearish towards the biotech sector, investors need to identify biotech stocks to avoid at this point.

Via InvestorPlace

Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million

July 05, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Wins FDA Approval For Highly Anticipated Gene Therapy ↗

June 22, 2023

Sarepta will sell the Duchenne muscular dystrophy gene therapy under the brand name Elevidys.

Via Investor's Business Daily

24 Analysts Have This to Say About Sarepta Therapeutics ↗

June 06, 2023

Via Benzinga

NASDAQ:SRPT Shareholder Notice: Investigation over Possible Wrongdoing at Sarepta Therapeutics, Inc. ↗

June 02, 2023

San Diego, CA -- (SBWIRE) -- 06/02/2023 -- An investigation was announced concerning possible breaches of fiduciary duties by certain directors at Sarepta Therapeutics, Inc.

Via SBWire

Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit

July 03, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 30, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%? ↗

June 30, 2023

While its gene therapy for Duchenne muscular dystrophy has been conditionally approved, it'll take a while to prove its merit.

Via The Motley Fool

Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)

June 27, 2023

Recent events surrounding Sarepta Therapeutics highlights the unpredictability of the biotech industry and its appropriateness solely for high-risk investors.

Via MarketBeat

Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 23, 2023

Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023 ↗

June 23, 2023

Via Benzinga

Canopy Growth, Avadel Pharmaceuticals And Other Big Stocks Moving Lower On Friday ↗

June 23, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. GSR II Meteora Acquisition Corp. (NASDAQ: GSRM)...

Via Benzinga

Sarepta Therapeutics' Therapy Becomes First To Score FDA Nod For Duchenne Muscular Dystrophy Gene Therapy ↗

June 22, 2023

The FDA has granted accelerated approval to closely watched Sarepta Therapeutics Inc's (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged...

Via Benzinga

Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy

June 22, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence ↗

June 20, 2023

Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a

Via Benzinga

3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon ↗

June 12, 2023

These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials.

Via InvestorPlace

How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run ↗

June 01, 2023

Shares surged into and out of the company's R&D Day, which included a surprise.

Via Investor's Business Daily

Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval? ↗

June 01, 2023

The stock has now given back all of its 2023 gains as investors' fears mount.

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 31, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com